| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
 |
|
Site Navigation
| ALS News & Research For postings of news or research links and articles related to ALS |
advertisement
| Reply |
|
|
Thread Tools | Display Modes |
|
|
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
09-27-2018, 09:16 AM
|
#1 | |||
|
||||
|
Grand Magnate
|
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS ibudilast to phase III study. Full scale phase III studies tend to be the most expensive and the final testing phase before marketing. IF they pass. |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Help for those with serious OFF periods - Positive Phase 3 Results for CVT-301 | Parkinson's Disease | |||
| AB Science Reports Positive Interim Results in Phase 3 Trial of Masitinib as an ALS | ALS News & Research | |||
| SYN115 Phase IIa; positive data | Parkinson's Disease | |||
| new member looking for positive feedback | New Member Introductions | |||
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ib
Linear Mode
